Gene therapy for wet AMD
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older.
- You have wet age-related macular degeneration (AMD) with active abnormal blood vessels.
- You have received at least 2 anti-VEGF injections (like Eylea or Lucentis) in the past 6 months, and they helped your vision.
- Your vision in the study eye is between about 20/80 and 20/800 (count fingers).
- You are willing to use birth control if needed, and to attend all follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
This study tests a new gene therapy called LX111 for diabetic macular edema (DME) that has not improved enough with previous injections. It aims to see if a single treatment can reduce swelling and improve vision.
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
This trial tests a new gene therapy called LX109 for wet age-related macular degeneration (nAMD). It is for patients who still need regular anti-VEGF injections, and the treatment aims to reduce how often you need those injections.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.